# Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

> **NCT07310186** · — · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **OTHER:** observational study

## Key facts

- **NCT ID:** NCT07310186
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310186, "Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07310186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*